Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its clinical-stage lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study. Tempest Therapeutics, Inc. is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.
Metrics to compare | TPST | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipTPSTPeersSector | |
---|---|---|---|---|
P/E Ratio | −1.1x | −5.3x | −0.7x | |
PEG Ratio | −0.03 | 0.10 | 0.00 | |
Price/Book | 5.0x | 2.1x | 2.6x | |
Price / LTM Sales | - | 81.5x | 3.4x | |
Upside (Analyst Target) | −16.2% | 200.6% | 35.7% | |
Fair Value Upside | Unlock | 3.3% | 4.1% | Unlock |